Surgical Science Sweden stock
SUS.STSTOSurgical Science Sweden AB (publ), HealthcareISIN SE0014428512
66Score 66 out of 100, Neutral
Price and trend
83 / 100
Price history
−34% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 43% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 34% below its 52-week high. Largest decline in 9 years: 93% (November 2021 to February 2026).
Chart figures for advanced users
- SMA 50$5.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.91
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.41
- The lowest closing price of the last twelve months.
- Resistance$8.47
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Surgical Science Sweden AB (publ) belongs to the Medical (Healthcare Information Services) industry (Sweden) and, with a market value of $285.66M, is number 25 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $99.92M (up 12.2% year on year) and earnings of $6.73M (down 49.2%).
- For fiscal 2026, analysts expect on average revenue of $103.22M (up 3.3%) and adjusted earnings per share of $0.22 (up 69.8%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 207 of 714 in Healthcare, median 53.
- The P/E is 30.5 (Medical (Healthcare Information Services) median 43, own median of recent years 52.5).
- Our model puts fair value at $9.28, with the price 32% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 56.8% a year since 2020, Medical (Healthcare Information Services) median 16.5%.Growth 100
- More cash than debtCash $66.29M, financial debt $287.66K.Stability 75
- Earnings per share growingUp 23.8% a year since 2020.Growth 100
Weaknesses
- DilutionShare count up 48% since 2020.Capital allocation 23
- Margin fallingOperating margin 11%, average of the prior years 20.3% (to 2024).Profitability 45
- Volatile share priceVolatility 81% a year over the last 12 months.
Its standout strengths are growth and technical analysis, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- high growth grade (crashed more often in the backtest)
- price up very strongly over the past year
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.19 and expensive above $18.56 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $10.65 (cash-flow model) and $7.91 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $8.29, at 6.2% it would be $10.78.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 8.4% on the twelve months before. Revenue has grown strongly since 2014, at around 34% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating 11%, net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 19 Aug 2026EPS reported $0.04 (expected $0.05)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.7% since 31 Oct 2026.
- Earnings per share
- $0.22+2.3%
- Revenue
- $103.22M+0.1%
- Earnings per share
- $0.32+3.7%
- Revenue
- $115M+0.1%
MEQIRI has stored the estimates since 31 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Surgical Science Sweden
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger companies by market value
- PhreesiaPHR $795.13M55
- SOPHiA GENETICSSOPH $635.9M47
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- NRC HealthNRC $570.01M59
- Evolent HealthEVH $561.28M45
- CarlsmedCARL $507.83M46
- GPIGPI.MI $480.24M44
- ClaritevCTEV $478.09M42
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Apr 2026)
- Valuation signal Fairly valued since 12 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.